Wednesday, August 12, 2026

Opparounds

🔬Psychiatric Research Article

Adolescent Mental Health Care and Stigma: The ARTEMIS Randomized Clinical Trial

Pallab K. Maulik, Sandhya Kanaka Yatirajula, Sudha Kallakuri, Srilatha Paslawar, Arpita Ghosh, Aman Rastogi, Ankita Mukherjee, Ritika Khan, Rajesh Sagar, Heidi Lempp, Ashok Kumar, Laurent Billot, Beverley M. Essue, Susmita Chatterjee, Renu Singh, David Peiris, Robyn Norton, Graham Thornicroft · JAMA Psychiatry · July 2026

This cluster-randomized trial tested a combined intervention across 60 slum clusters in New Delhi and Vijayawada, India: a multimedia antistigma campaign aimed at adolescents, paired with a primary-care-worker-led digital tool to identify and manage depression risk. Of 3,739 adolescents enrolled, 1,761 (47.1%) were identified as high risk for depression or self-harm. Stigma-related behavioral intention scores improved significantly more in intervention clusters than control (17.22 vs 16.44; P<.001), and among high-risk adolescents, PHQ-9 scores improved more with the intervention (4.05 vs 4.92; P=.03).

Depression remission was numerically higher in the intervention arm (68.2% vs 59.4%) but didn't reach significance (P=.10), and campaign fidelity stayed high — 90% of adolescents received the antistigma elements as designed.

💡 Why it matters

Reducing stigma and improving depression care were paired, not separate goals here — the antistigma campaign moved a symptom outcome (PHQ-9), which is the strongest evidence yet that stigma reduction is a clinical intervention, not just an awareness campaign.

Read the paper → doi:10.1001/jamapsychiatry.2026.0603

🩺General Medicine Article

Adjunctive Fecal Microbiota Transplantation for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

Jing Li, Yaping Wang, Ruinan Li, Huanwei Huang, Xuequan Zhu, Xiaozheng Li, Zuoli Sun, Ling Zhang, Peng Zheng, Yi He, Jing Liu, Xueshan Zhang, Siyu Ren, Mingxia Liu, Haixia Wang, Yanting Luo, Fei Wang, Jingjing Zhou, Jian Yang, Gang Wang · Cell Host & Microbe · July 2026

Patients with major depressive disorder starting escitalopram were randomized to also receive a 2-week course of oral FMT capsules (from screened donors) or placebo capsules. FMT produced significantly greater reductions in HAMD-17 scores than placebo at both week 2 and week 8, and week-8 remission was numerically higher with FMT (43.3% vs 26.7%), though the trial wasn't powered to call that difference definitive. FMT was well tolerated, with an adverse-event profile comparable to placebo.

Multi-omics analysis showed durable engraftment of donor microbes, enrichment of Lachnospiraceae and Oscillospiraceae, and a rise in serum bile acids that correlated with symptom improvement — a plausible gut-to-brain mechanism rather than just a correlation.

💡 Why it matters

This is one of the more mechanistically grounded gut-microbiome-depression trials to date — worth knowing about now, since adjunctive microbiome-targeted treatment for depression is likely to keep showing up in the literature over the next few years.

Read the paper → doi:10.1016/j.chom.2026.05.017

💊Psychiatric Fact

Fentanyl broke the old buprenorphine induction rules

The classic teaching — wait for a COWS score of 12 to 13, then start standard induction — was calibrated on heroin and short-acting prescription opioids, not fentanyl. Fentanyl's high lipophilicity means it sequesters in fat and keeps releasing back into circulation long after it should be cleared, so patients can still precipitate into withdrawal from buprenorphine's partial-agonist displacement days after their last reported use, even when they look clinically ready by COWS.

Two practical changes follow. Low-dose ("microdose") induction — starting buprenorphine at 0.5 mg or lower while the patient continues their full agonist, then titrating up over 4 to 7 days — avoids triggering withdrawal at all. And standard-dose induction after known fentanyl exposure should lean on objective signs over self-reported timing, since patients reliably underestimate how much fentanyl-contaminated supply they've actually had. Precipitated withdrawal is the single most common reason a buprenorphine induction fails and a patient leaves before the medication gets a chance to work.

🛋️Psychotherapy Teaching Pearl

Opposite action for shame only works after you've sorted justified from unjustified

DBT's opposite-action skill is often taught as a blanket rule — feel an urge, do the reverse — but for shame specifically, the technique starts with a judgment call the therapist makes explicitly with the patient: is this shame justified or unjustified? Justified shame, where the emotion fits the facts and one's own values, calls for repair, not opposite action. Unjustified shame — the far more common presentation, where a patient feels shame about a trauma history, a diagnosis, or an identity, with no actual violation of their own values — is where opposite action applies.

Shame's urge is to hide: avert eyes, shrink, disappear from view. The opposite action is active engagement — eye contact, disclosing the exact thing the patient wants to hide, staying visible instead of leaving the room. Skip the justified/unjustified sort and opposite action turns into a way to bypass legitimate guilt, instead of treating shame that shouldn't be there in the first place.

🗒️ Vignette

In a DBT skills group, a patient discloses a past suicide attempt, then immediately looks down, arms crossed: "I shouldn't have said that, that's disgusting." The therapist checks the facts first — no violation of her own values, no harm to others — this is unjustified shame.

Rather than reassuring her verbally, the therapist has her practice the opposite action in the room: sit up, uncross her arms, make eye contact with the group, and repeat the disclosure once more without qualifying it. She does, visibly shaking. The group's response — no one flinches — becomes the corrective experience the words alone couldn't provide.